While headline pharmaceutical research and development (R&D) returns have improved for the third consecutive year, reaching a 7.0 percent internal rate of return (IRR) in 2025, this recovery is largely driven by a few mega-blockbuster programs, notably glucagon-like peptide receptor agonists (GLP-1s) and GLP-1 combinations with gastric inhibitory polypeptide-based drugs (GIPs) in obesity, masking broader R&D pressures
Implementation Barriers and Access to Care Although newer obesity pharmacotherapies demonstrate substantial efficacy, their real-world population-level impact is strongly influenced by cost, insurance coverage, and health-system capacity [101]
#antipsychotics #clinicalresearch #digitalhealth #digitaltherapeutics #DTx #ECNP #healthtech #medicalaffairs To view or add a comment, sign in Uzedy: New FDA Approval for Bipolar I Disorder Im launching a monthly series highlighting new drug approvals and innovations in CNS, psychoactive molecules, and neuroscience
Sermorelin was previously approved as Geref and was withdrawn from the brand market for commercial reasons